A First-in-Human Study of CEE321 in Adult Subjects

Status:
Completed

Trial end date:
2021-05-16

Target enrollment:

Participant gender:

Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis

Phase 1

Novartis Pharmaceuticals